Company Profile

JAGSONPAL PHARMACEUTICALS LTD.

NSE : JAGSNPHARMBSE : 507789ISIN CODE : INE048B01027Industry : Pharmaceuticals & DrugsHouse : Jagsonpal
BSE63.30-0.25 (-0.39 % )
PREV CLOSE (Rs.) 63.55
OPEN PRICE (Rs.) 64.75
BID PRICE (QTY) 62.80 (200 )
OFFER PRICE (QTY) 63.30 (223 )
VOLUME 8559
TODAY'S LOW / HIGH (Rs.)62.00 65.45
52 WK LOW / HIGH (Rs.)16 76.1
NSE62.80 -0.9 (-1.41 % )
PREV CLOSE(Rs.) 63.70
OPEN PRICE (Rs.) 63.00
BID PRICE (QTY) 62.80 (277 )
OFFER PRICE (QTY) 63.20 (20 )
VOLUME 94738
TODAY'S LOW / HIGH(Rs.) 62.20 65.85
52 WK LOW / HIGH (Rs.)16.25 76.05

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 5.417847
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 4.96
ROCE (%) 9.53
Incorporation Year : 1978

Management Info :

R P S Kochhar - Chairman R P S Kochhar - Managing Director

Registered Office :

Address : T 210 J,Shabpur Jat, ,
New Delhi,
Delhi-110049

Phone : 011-46181100 & 46119900

Website : www.jagsonpal.com

Registrar's Details : MCS Ltd
F-65, ,Okhla Industrial Area,Phase - I,New Delhi
Listing : BSE, NSE, MCX
NEWS More
28Oct10-28-2020$Jagsonpal Pharmaceuticals informs about certificate Jagsonpal Pharmaceuticals in

In terms of sub-regulation 9 & 10 of Regulation 40 of SEBI of (Listing Obligations And Disclosure Requirement) Regulations 2015, Jagsonpal Pharmaceuticals has informed that it has enclosed a Certificate dated 27/10/2020 certified by Mukesh Arora & Co., Practicing Company Secretary for the half year ended 30th September, 2020.

The above information is a part of company’s filings submitted to BSE.

In terms of sub-regulation 9 & 10 of Regulation 40 of SEBI..
01Jul07-01-2020$Jagsonpal Pharmaceuticals informs about annual secretarial compliance report Jagsonpal Pharmaceuticals in

Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019, Jagsonpal Pharmaceuticals has informed that it has enclosed the Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2020.

The above information is a part of company’s filings submitted to BSE. 

Pursuant to Regulation 24A of the SEBI (Listing Obligations and..
13Feb02-13-2020$Jagsonpal Pharmaceuticals informs about outcome of board meeting Jagsonpal Pharmaceuticals in

Jagsonpal Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held today, the13th February, 2020), approved and taken on record Un-Audited Financial Results of the Company for the Quarter and nine months ended 31st December, 2019; and Limited Review Report for the Quarter and Nine Months ended 31st December 2019.

The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has informed that the Board of Direct..
Financials More
Rs. in Millions
QTR Sep 20 ANNUAL 20
Net Profit40.069999999999978.6999999999999
Gross Profit 48.5499999999999 94.1399999999999
Operating Profit 52.4699999999999110.58
Net Sales 563.531585.68
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Procter&Gamble Healt (BSE)
 6545.00 (3.01%)
M.Cap ( in Cr)
10874.75
Abbott India (BSE)
 15425.00 (0.40%)
M.Cap ( in Cr)
32704.16
JB Chem & Pharma (BSE)
 989.15 (3.87%)
M.Cap ( in Cr)
7659.43
Neuland Laboratories (BSE)
 1034.15 (3.43%)
M.Cap ( in Cr)
1318.34
Sanofi India (BSE)
 8281.95 (0.36%)
M.Cap ( in Cr)
19074.88
Shareholding Pattern More
PROMOTERS 70.34 %
NON-INSTITUTION 29.66 %
FI/BANKS/INSURANCE 0 %
MUTUAL FUNDS/UTI 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
Scheme NameHold(%)
Taurus Starshare (Multi...1.99
F & O Quotes